This paper is in the following e-collection/theme issue:

Viewpoint and Opinions on Technology and Innovation in Public Health (47) Innovative Methods in Public Health and Surveillance (307) Surveillance Systems (430) Health Services in Resource-Poor Settings and LMICs (376)

Published on in Vol 7, No 8 (2021): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/29309, first published .
Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance

Authors of this article:

Elizabeth Pisani1, 2, 3 Author Orcid Image ;   Amalia Hasnida1 Author Orcid Image ;   Mawaddati Rahmi3 Author Orcid Image ;   Maarten Olivier Kok1, 4 Author Orcid Image ;   Steven Harsono5 Author Orcid Image ;   Yusi Anggriani3 Author Orcid Image
Article Authors Cited by (7) Tweetations (5) Metrics

Journals

  1. Chabalenge B, Jere E, Nanyangwe N, Hikaambo C, Mudenda S, Banda M, Kalungia A, Matafwali S. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems. The Journal of Medicine Access 2022;6:275508342211417 View
  2. Pozsgai K, Szűcs G, Kőnig-Péter A, Balázs O, Vajda P, Botz L, Vida R. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study. Frontiers in Pharmacology 2022;13 View
  3. Dewi A, Patel A, Palagyi A, Praveen D, Ihsan B, Hariadini A, Lyrawati D, Sujarwoto S, Maharani A, Tampubolon G, Jan S, Pisani E. A study of the quality of cardiovascular and diabetes medicines in Malang District, Indonesia, using exposure-based sampling. BMJ Global Health 2022;7(11):e009762 View
  4. Pyzik O, Abubakar I. Fighting the fakes: tackling substandard and falsified medicines. Nature Reviews Disease Primers 2022;8(1) View
  5. MohanaSundaram A, Padhi B, Mohanty A, Shrestha S, Sah R. The silent epidemic of substandard and falsified medicines in low- and middle-income countries: heed lessons from the tragic deaths of children in Indonesia. International Journal of Surgery 2023;109(3):523 View
  6. Shrivastava S, Nurhidayati R. Substandard and Falsified Medical Products: Time to Arrest Their Growth. Libyan International Medical University Journal 2023;08(02):089 View
  7. Arsovska A, Acevska J, Brezovska K, Godzo H, Dimitrovska A. Risk-based assessment of the possibility for falsification during post-marketing surveillance of medicines. Macedonian Pharmaceutical Bulletin 2023;69(03):229 View